



EUROGIN

INTERNATIONAL MULTIDISCIPLINARY HPV CONGRESS
WWW.EUROGIN.COM

DÜSSELDORF
APRIL 10 - 12
2022

PROGRAM OVERVIEW

- FDW - Full Day Workshop**
Revisiting high-grade intraepithelial neoplasia - molecular biology, risk management and prevention
- MSS - Main Scientific Session**
- SS - Scientific Session**
- CS - Clinical Session**
- HN - HPV and Head & Neck Forum**
- FC - Free Communication**
- WS - Specialized Workshop**
- Colposcopy Course**
Separate registration required
- LW - Local Workshop**
HPV 2022 - Über die Wissenschaft zur Praxis
- Workshop Francophone Virtuel**
- Satellite Symposium**

Session On-Demand (SOD)

SUNDAY, APRIL 10

	Hall X	Room 14	Room 15	Room 16a	Room 16b	
8.15				Colposcopy Course • Welcome		8.15
8.30	FDW 01A • Cervix The Global picture of CIN3-ADC in situ	SS 01 • Epidemiology: HIV and HPV-related cancers		Colposcopy Course Part A	FC 01 • Screening methods and triage I	8.30
9.30	COFFEE BREAK			COFFEE BREAK	COFFEE BREAK	
10.00	FDW 01B • Cervix HPV primary screening of CIN3-ADC in situ: new insights and long-term performance	COFFEE BREAK		Colposcopy Course Part B	FC 02 • Screening methods and triage II	10.00
10.30		FC 03 • Vaccines I	FC 04 • Viral and molecular biology	COFFEE BREAK	COFFEE BREAK	10.30
11.45				LUNCH BREAK	LUNCH BREAK	12.00
12.00	Satellite Symposium	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	
13.15						13.30
13.30	FDW 01C • Cervix HPV vaccines: protection against CIN3-ADC in situ	SS 02 • Is HPV genotyping transforming primary HPV screening?	WS 01A • The feasibility of personalized screening in organized programs	SS 04 • HPV and anal cancer diseases - screening	FC 05 • Methylation	13.30
15.00	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	15.00
15.30	FDW 01D • Cervix Management and follow-up of women with CIN3-ADC in situ	SS 03 • Quality assurance of self-sampling for cervical screening and disease management	WS 01B • The feasibility of personalized screening in organized program		FC 06 • Epidemiology, natural history and public health I	15.30
17.00				WS 02 • Prevention of anal cancer post-ANCHOR	FC 07 • Epidemiology, natural history and public health II	
18.30			Satellite Symposium			18.30

18.45 - Opening Ceremony

MONDAY, APRIL 11

	Auditorium Room 1	Hall X	Room 14	Room 15	Room 16a	
8.15	MSS 01A • HPV diseases and SARS-Cov-2 COVID-19 and HPV vaccination	CS 01 • New strategies for monitoring disease in the test of cure population	SS 05 • The utility of urine for improved cervical cancer prevention	FC 08 • Vaccines II	FC 10 • Diagnostic procedures and management	8.00
9.30	MSS 01B • HPV diseases and SARS-Cov-2 COVID-19 and cervical cancer screening	CS 02 • Cervical adenocarcinoma in situ: a review	SS 06 • Challenges in new assays for cervical cancer screening of screen+ women	FC 09 • Vaccines III	FC 11 • HPV testing	9.30
11.00	COFFEE BREAK					11.00
11.30	Satellite Symposium	LUNCH BREAK				
12.45			LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	
14.00						14.00
14.00	MSS 02 • HPV vaccines - Special session	SS 07A • Targeting high risk populations - Screening	FC 12 • HPV disease and COVID-19	FC 14 • Self-sampling I	HN 01 • Screening, prevention and epidemiology	14.00
15.00		SS 07B • Targeting high risk populations - Vaccination				15.30
15.30	COFFEE BREAK		COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	15.30
16.00	MSS 03 • New evidence on the effectiveness of HPV vaccination against invasive cervical cancer: a global view	SS 08 • Screening in special situations: from evidence to practical guidance	FC 13 • Microbiome	FC 15 • Self-sampling II	HN 02 • Survivorship & surveillance	16.00
17.30						17.30
18.00				Workshop Francophone Virtuel Contrôle en vie réelle des cancers HPV induits	HN 03 • Management / Clinical trials	17.30
18.45						19.00

TUESDAY, APRIL 12

	Room X	Room 14	Room 15a	Room 15b	Room 16a	
8.00	MSS 04 • Routine HPV screening: how to modulate and manage HPV screening by age	SS 09 • Artificial intelligence and digital pathology applications in cancer screening	SS 10 • HPV latency and clinical implications	LW 01 • HPV-Impfung	HN 04 • Submitted papers	8.00
9.30	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	9.30
10.00	MSS 05 • HPV vaccination strategies, impact and safety by age, current knowledge	CS 03 • New developments in colposcopy practice	SS 11 • Innovative SARS-CoV-2 diagnostic devices: opportunity for worldwide HPV screening	LW 02 • Gesundheitspolitik und Prävention	SS 12 • The role of HPV ct DNA for the surveillance of recurrence in HPV-associated cancer	10.00
11.30						11.30
11.45	Satellite Symposium	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	
13.00						13.15
13.15	MSS 06 • Assessing risk of cervical cancer in the post vaccination era	SS 13 • Gaps in knowledge and promising research directions in HPV and cancer	WS 03A • Vulvar diseases workshop	LW 03A • Zervixkarzinomscreening in Deutschland und international	HN 05 • Carcinogenesis & molecular characterization	13.15
14.45	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	LW 03B • Zervixkarzinomscreening in Deutschland und international	COFFEE BREAK	14.20
15.00				COFFEE BREAK		14.45
15.30	MSS 07A • HPV screening: first experiences HPV screening, the first experiences	CS 04 • Clinical applications of emerging sequencing technologies			HN 06 • Immunologic considerations	15.15
16.45	MSS 07B • HPV screening: first experiences HPV self-sampling	CS 05 • Applying methylation assays for clinical use	WS 03B • Vulvar diseases workshop Stump the expert	LW 04 • Differenzialdiagnostik bei auffälligem Screeningbefund	FC 16 • Immunology and immunotherapy	15.30
18.00						16.00
18.15						16.45
						17.30
						18.00
						18.15